Zhai Ting, Li Yi, Brown Robert, Lanuti Michael, Gainor Justin F, Christiani David C
Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Cancer Med. 2025 May;14(10):e70962. doi: 10.1002/cam4.70962.
Residual volume (RV) / total lung capacity (TLC) ratio has been found to better predict functional impairments than spirometry and is associated with mortality in chronic obstructive pulmonary disease; however, it is rarely studied in lung cancer. Our previous work established spirometry as a prognostic factor for lung cancer, and we aimed to further investigate the prognostic value of TLC and RV in lung cancer patients.
We identified newly diagnosed non-small cell lung cancer (NSCLC) patients who underwent static lung function tests prior to any cancer therapy between 1992 and 2020 in a longitudinal cohort of lung cancer patients: the Boston Lung Cancer Study. Cox proportional-hazards model was used to estimate the association between each lung volume test with overall survival.
Among 2348 NSCLC patients, 57.2% were diagnosed at stage I and 63.8% underwent surgery, with 1352 deaths observed over a median survival of 66.9 months. Higher RV, RV%, and lower TLC, TLC% were associated with worse overall survival marginally; RV/TLC was associated with overall survival as a quantitative trait, with one standard deviation (11.24%) increase in RV/TLC associated with 19.2% higher risk of mortality (HR = 1.192 [95% CI: 1.114, 1.277]) after covariate adjustment. Statistically significant interactions were found between RV/TLC and spirometry, and higher mortality risks were found with higher RV/TLC in patients across spirometry status and cancer stages.
NSCLC patients with higher RV/TLC ratios at diagnosis had worse overall survival, even when spirometry was within the predicted range. These findings suggest that lung volume measurements provide prognostic information beyond standard spirometry, supporting the need for further mechanistic and interventional studies to determine their clinical utility.
已发现残气量(RV)/肺总量(TLC)比值比肺功能测定更能准确预测功能损害,且与慢性阻塞性肺疾病的死亡率相关;然而,在肺癌中对此研究较少。我们之前的工作已确定肺功能测定是肺癌的一个预后因素,我们旨在进一步研究TLC和RV在肺癌患者中的预后价值。
我们在一个肺癌患者纵向队列(波士顿肺癌研究)中,确定了1992年至2020年间在接受任何癌症治疗之前接受过静态肺功能测试的新诊断非小细胞肺癌(NSCLC)患者。使用Cox比例风险模型来估计每次肺容量测试与总生存期之间的关联。
在2348例NSCLC患者中,57.2%在I期被诊断出来,63.8%接受了手术,在中位生存期66.9个月期间观察到1352例死亡。较高的RV、RV%,以及较低的TLC、TLC%与总体生存期略差相关;RV/TLC作为一个定量性状与总生存期相关,在协变量调整后,RV/TLC增加一个标准差(11.24%)与死亡风险高19.2%相关(风险比[HR]=1.192[95%置信区间:1.114,1.277])。发现RV/TLC与肺功能测定之间存在统计学上显著的相互作用,并且在不同肺功能状态和癌症分期的患者中,RV/TLC越高,死亡风险越高。
诊断时RV/TLC比值较高的NSCLC患者总体生存期较差,即使肺功能测定在预测范围内。这些发现表明,肺容量测量提供了超出标准肺功能测定的预后信息,支持需要进一步进行机制和干预研究以确定其临床效用。